IAMA Therapeutics

Iama Therapeutics is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children suffering from brain disorders. Intracellular chloride (Cl) homeostasis is impaired in many brain disorders, including autism spectrum disorder and epilepsy, due to dysregulated activity of Cl-transporters.

Restoring physiological intracellular Cl homeostasis in the brain by inhibiting the Sodium Potassium Chloride cotransporter 1 (NKCC1) or activating the Sodium Chloride cotransporter 2 (KCC2), members of the same family of transporters but with opposing effects has proven a viable strategy for treating many neurodevelopmental disorders in animal models and clinical studies.

We have identified and patented a novel compound class that inhibits NKCC1 with high selectivity and backup and follow-up molecules targeting other cotransporters.

We aim to improve the lives of children by promoting intracellular homeostasis and reducing the hyperexcitability of some neuronal cells in pathological conditions."